Placebo News and Research

RSS

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Lexicon Pharmaceuticals, Inc.'s telotristat etiprate, the first oral therapy in development for the treatment of carcinoid syndrome (CS), was associated with patient-reported improvements in social and physical function and emotional well-being according to new exit interview data from the Phase 3 TELESTAR study presented at the 2015 Neuroendocrine Tumor Society Annual Symposium in Austin, Texas.

19 Oct 2015

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

Sprout Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC, announced today that Addyi, a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now available in the United States through certified physicians and pharmacies.

19 Oct 2015

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

TARSA Therapeutics, Inc. today announced that its New Drug Application (NDA) for TBRIATM (calcitonin-salmon [rDNA origin] delayed release tablets) submitted to the U.S. Food and Drug Administration (FDA) in July 2015, has been accepted for review, with a PDUFA date of May 30, 2016.

19 Oct 2015

Study shows vitamin D, calcium supplements fail to protect against colorectal cancer

A large, randomized study at 11 U.S. hospitals including Dartmouth-Hitchcock Medical Center found that vitamin D and calcium supplements fail to protect against developing colorectal cancer.

16 Oct 2015

Medical experts launch crowd funding project to investigate effect of malaria drug on colorectal cancer

Medical experts investigating whether a common malaria drug could have a significant impact on colorectal cancer have launched a crowd funding project to fund their work.

16 Oct 2015

GATE opens for generic equivalent to glatiramer acetate in MS

Findings from the GATE study have shown equivalent efficacy and tolerability for a generic version of glatiramer acetate to that of the original brand version in the treatment of relapsing–remitting multiple sclerosis.

15 Oct 2015

Omeros launches OMIDRIAssure program to provide expanded patient access to Omidria

Omeros Corporation today announced that it has launched OMIDRIAssure, a comprehensive reimbursement services program to provide expanded access to Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% for cataract surgery patients and reimbursement assistance for physicians and facilities.

15 Oct 2015

Researchers one step closer to finding effective drug for alcohol dependence

Researchers at Karolinska Institutet and the Sahlgrenska Academy in Sweden might be one step closer to finding an effective drug for alcohol dependence. In two separate studies, they show that the so-called dopamine stabilizer OSU6162 can reduce the craving for alcohol in alcohol dependent people and normalises the level of dopamine in the brain reward system of rats that have consumed alcohol over a long period of time.

14 Oct 2015

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

The Scottish Medicines Consortium has today announced that Xofigo has been accepted for use within NHS Scotland for the treatment of adult patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

13 Oct 2015

Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.

13 Oct 2015

Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

In a Sutter Institute of Medical Research study published this month in the Journal of Neurology, Neurosurgery, and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, was found to reduce brain atrophy and cognitive decline in patients in the early, pre-dementia phase of Alzheimer's disease.

12 Oct 2015

New clinical study focuses on investigational treatment to reduce impact of key protein from the brain

The Nantz National Alzheimer Center at Houston Methodist Hospital is part of a landmark clinical trial that looks at removing a key protein from the brain to prevent memory loss at least a decade before symptoms are noticed in healthy older adults.

12 Oct 2015

Researchers explore how nitrate-rich beet juice may affect high altitude acclimatization

Ever since human beings first began climbing the world's tallest mountains, they have struggled with a basic problem: altitude sickness, caused by lower air pressures which affect the ability of our bodies to take up oxygen.

12 Oct 2015

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced the Company's oncology drug candidate, CF102, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the indication of hepatocellular carcinoma (HCC), the most common form of liver cancer.

12 Oct 2015

Lithium can be safe, effective for children suffering from bipolar disorder

A multicenter study of young patients with bipolar disorder provides what may be the most scientifically rigorous demonstration to date that lithium -- a drug used successfully for decades to treat adults with the condition -- can also be safe and effective for children suffering from it.

12 Oct 2015

Phase III studies show Roche's ocrelizumab reduces relapse rate, delays disability progression in MS patients

Three phase III studies being presented at the European Committee for Treatment Research in Multiple Sclerosis congress demonstrate that treating MS with ocrelizumab reduces relapse rate and delay onset of disability progression compared to interferon beta-1a in relapsing forms of MS and disability progression in primary progressive MS compared to placebo.

12 Oct 2015

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

The U.S. Food and Drug Administration today approved Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies.

9 Oct 2015

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen.

9 Oct 2015

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks.

9 Oct 2015

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic and highly emetogenic) cancer chemotherapy.

9 Oct 2015

Placebo News and Research

Lexicon's telotristat etiprate improves social and physical function, emotional well-being in cancer patients

Sprout announces U.S. availability of Addyi for HSDD treatment in premenopausal women

TARSA Therapeutics' TBRIA NDA accepted by FDA for review

Study shows vitamin D, calcium supplements fail to protect against colorectal cancer

Medical experts launch crowd funding project to investigate effect of malaria drug on colorectal cancer

GATE opens for generic equivalent to glatiramer acetate in MS

Omeros launches OMIDRIAssure program to provide expanded patient access to Omidria

Researchers one step closer to finding effective drug for alcohol dependence

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Study shows that IVIG could prevent brain atrophy, delay onset of Alzheimer's disease

New clinical study focuses on investigational treatment to reduce impact of key protein from the brain

Researchers explore how nitrate-rich beet juice may affect high altitude acclimatization

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Lithium can be safe, effective for children suffering from bipolar disorder

Phase III studies show Roche's ocrelizumab reduces relapse rate, delays disability progression in MS patients

FDA approves Lonsurf drug for patients with advanced form of colorectal cancer

FDA approves Promacta to treat pediatric patients with chronic immune thrombocytopenic purpura

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

Varubi (rolapitant) approved to prevent delayed phase chemotherapy-induced nausea and vomiting

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News